OncTimes Talk

OncTimes Talk

By Oncology TimesMedicineHealth & Fitness
Download on the App Store

OncTimes Talk episodes

  • Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers

    Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024.

    The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease progression among patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction cancers reported from Chinese investigators.

    The first author of the report, Jiafu Ji, MD, PhD, DrPH, FACS, FRCS, Fellow of the Chinese Academy of Medical Science, as well as Professor and Chief of the Gastrointestinal Cancer Center at Peking University Cancer Hospital and the Beijing Institute for Cancer Research in China, called into the Oncology Times office at AACR after his talk to discuss his team's findings with Peter Goodwin, an OncTimesTalk correspondent.

    10 min
  • Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma

    Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting.

    After giving his talk in San Diego, lead author Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology and Director of the Center of Excellence for Multiple Myeloma at the Icahn School of Medicine at Mount Sinai in New York, met up with OncTimesTalk correspondent Peter Goodwin to discuss the therapeutic progress the drug offers.

    16 min
  • Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection

    An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells.

    At the AACR Annual Meeting 2024 in San Diego, Peter Goodwin talked with Ajay Goel, PhD, AGAF, senior author of the study and Chair of the Molecular Diagnostics and Experimental Therapeutics in the Beckman Research Institute at City of Hope in Los Angeles.

    13 min
  • Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers

    Designed with the help of artificial intelligence to recognize multiple genetic features of each patient's tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in some patients.

    At the AACR Annual Meeting 2024, Olivier Lantz, MD, PhD, Head of the Clinical Immunology Laboratory at the Institut Curie Hospital in Paris, reported data using a "neoantigen-based vaccine" specifically designed to recognize multiple genetic features unique to each patient's tumor. During the conference, Lantz called into the OncTimesTalk studio to tell Peter Goodwin about the clinical options that could develop from such highly personalized vaccines.

    14 min
  • Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery

    Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer.

    At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplinary Breast Centre at the Technical University of Munich in Germany, said the technique prevents the unnatural breast mobility patients can experience after reconstruction, sometimes called jumping breasts.

    After reporting his group's 24-month follow-up data from the prospective international mesh-supported, pre-pectoral breast reconstruction trial (PRO-Pocket Trial) at the conference, he discussed the findings with Peter Goodwin.

    11 min
  • Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed

    The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable efficacy for the two boost regimens, with less toxicity among patients receiving the low boost.

    The trial findings were reported by Sophie Bosma, MD, PhD, Radiation Oncologist from The Netherlands Cancer Institute in Amsterdam at the 14th European Breast Cancer Conference held in Milan. After her talk, she discussed the findings with Peter Goodwin.

    9 min
  • Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain

    A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving therapy for ductal carcinoma in situ (DCIS) had become increasingly effective in preventing the emergence of breast cancer over the long term, but that there were still unanswered questions.

    The population-based Netherlands Cancer Registry retrospective cohort study of 25,719 women with DCIS diagnosed from 1989 up to 2021 (all of whom were treated with standard conservative therapy) found there were successes and limitations with the current standard of care for DCIS.

    Surprisingly, long-term risk appeared to have been unrelated to tumor grade. Also, despite a continuing improvement in outcomes during this period, the investigators concluded that specific molecular predictors of outcome still needed to be identified to distinguish intrinsically low-risk tumors (that did not require even conservative therapy) from those that carry higher risk and are highly likely to benefit from breast-conserving surgery and radiotherapy.

    After reporting the study findings in Milan, study author Adri Voogd, PhD, Associate Professor of Clinical Epidemiology in the Faculty of Health, Medicine, and Life Sciences at Maastricht University, Maastricht, The Netherlands, discussed their clinical implications with Peter Goodwin.

    16 min
  • Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection

    Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands.

    Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department of the Antoni van Leeuwenhoek-Netherlands Cancer Institute in Amsterdam, The Netherlands, reported her findings from a study using the MARI protocol (marking axillary lymph nodes with radioactive iodine seeds) that predicts cancer outcomes. The protocol was developed at the AVL Hospital in 2014 and is now being used in several Dutch hospitals.

    After her session at the Milan conference, van Hemert talked with OncTimesTalk correspondent Peter Goodwin about the clinical implications of her group's findings.

    10 min
  • Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer

    Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference.

    The researchers found that single-dose, MRI-guided, partial breast irradiation given before breast-conserving surgery achieved durable pathologic complete remissions in low-risk breast cancer, as well as held out the prospect of surgery-free treatment for some patients.

    After giving her talk in Milan, Civil discussed the details of the ABLATIVE study findings with Peter Goodwin.

    10 min
  • Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer

    Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers.

    These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Research at the University of Texas Southwestern Medical Center.

    After McArthur's talk in Italy, she shared the details with Peter Goodwin, OncTimesTalk correspondent.

    10 min

About OncTimes Talk

From the publisher's feed

OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.